Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro
- PMID: 3075357
- DOI: 10.1016/0035-9203(88)90208-8
Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro
Abstract
A comparative study showed that 5 laboratory strains of Trypanosoma cruzi could be divided into a non-responsive group (Sonya clone and Colombiana) and a responsive group (Tulahuén, Y and Peru), based on long-term treatment of mouse infections with nifurtimox and benznidazole. In vitro sensitivity of epimastigotes and blood-stream trypomastigotes in macrophage cultures did not distinguish the strains, nor did the rate of development of nifurtimox resistance by epimastigote cultures. 7 novel anti-T. cruzi compounds also behaved similarly with respect to the 2 groups. A small decrease in sensitivity was observed in vitro by non-responsive strains of T. cruzi after re-isolation from treated mice. It is postulated that there could be an immunological component involved in successful treatment of T. cruzi infection.
Similar articles
-
Role of glutathione in the susceptibility of Trypanosoma cruzi to drugs.Comp Biochem Physiol C Comp Pharmacol Toxicol. 1989;94(1):87-91. doi: 10.1016/0742-8413(89)90148-5. Comp Biochem Physiol C Comp Pharmacol Toxicol. 1989. PMID: 2576749
-
Trypanocidal activity of N-isopropyl oxamate on cultured epimastigotes and murine trypanosomiasis using different Trypanosoma cruzi strains.J Enzyme Inhib Med Chem. 2005 Apr;20(2):189-97. doi: 10.1080/14756360500047019. J Enzyme Inhib Med Chem. 2005. PMID: 15968824
-
Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.Trans R Soc Trop Med Hyg. 1987;81(5):755-9. doi: 10.1016/0035-9203(87)90020-4. Trans R Soc Trop Med Hyg. 1987. PMID: 3130683
-
The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.Acta Trop. 2020 Jan;201:105218. doi: 10.1016/j.actatropica.2019.105218. Epub 2019 Oct 11. Acta Trop. 2020. PMID: 31610148 Review.
-
Current drug therapy and pharmaceutical challenges for Chagas disease.Acta Trop. 2016 Apr;156:1-16. doi: 10.1016/j.actatropica.2015.12.017. Epub 2015 Dec 30. Acta Trop. 2016. PMID: 26747009 Review.
Cited by
-
The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance.Front Cell Infect Microbiol. 2022 Jul 29;12:926699. doi: 10.3389/fcimb.2022.926699. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35967878 Free PMC article.
-
Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.Sci Rep. 2014 Apr 16;4:4703. doi: 10.1038/srep04703. Sci Rep. 2014. PMID: 24736467 Free PMC article.
-
State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation.Res Rep Trop Med. 2023 Jun 14;14:1-19. doi: 10.2147/RRTM.S415273. eCollection 2023. Res Rep Trop Med. 2023. PMID: 37337597 Free PMC article. Review.
-
Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites.Antimicrob Agents Chemother. 2005 Jul;49(7):2701-9. doi: 10.1128/AAC.49.7.2701-2709.2005. Antimicrob Agents Chemother. 2005. PMID: 15980339 Free PMC article.
-
Interaction of Trypanosoma cruzi, Triatomines and the Microbiota of the Vectors-A Review.Microorganisms. 2024 Apr 25;12(5):855. doi: 10.3390/microorganisms12050855. Microorganisms. 2024. PMID: 38792688 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources